text:
Food training means feeding your dog at regular intervals and setting expectations about how he behaves. Food training is important to your dog's health for a few reasons. It helps with portion control so your dog can maintain a healthy weight. Free-feeding or giving your dog unlimited access to food can lead to overeating.
Regular feeding also helps you monitor your dog's eating behaviour. Changes in eating patterns are one of the first signs of a health issue. You're more likely to notice a problem sooner if you're feeding set amounts in set intervals.
Food training also helps establish positive behaviours about eating. If dogs know what to expect, they won't be as possessive about food or show signs of aggression at feeding time. This also helps your dog identify you as the source of food. When free-feeding, it's more difficult for your dog to understand where food comes from.
Feed your pet three times daily for a specific time period, usually about 20 minutes, and then remove the food. Soon, your dog will understand the concept of mealtimes and look to you at feeding time.
Contrary to popular belief, your meal times do not need to be exact. Rather, they should be approximate, or within a window of a few hours. This way, your dog will not become pushy and demanding at an exact time each day. Your dog will come to trust that food is on its way, even if it's not exactly 5 p.m.
If dogs seem to be possessive about a bowl, you can curb this behaviour with some simple training techniques:
From then on, your dog should be comfortable with you nearby during eating times. Occasionally, swirl your hand in the bowl or sit near while your dog feeds to refresh the training.
Sources Ezine Articles. Training Your Dog to Good Feeding Habits. Dog Training Basics. Leadership, Respect … and the Dog Food Bowl.
Get step-by-step instructions for teaching your dog basic commands.
Our biscuits and treats are perfect for training your dog or as a special snack.
Nourish your dog with NATURAL CHOICE® WHOLESOME ESSENTIALS® Dog Food.


text:
Center & Clinics
Orthopedics Center
Vejthani Hospital Orthopedics Center is one of the best orthopedics groups in Bangkok specializing in the care of the musculoskeletal system. As board certified orthopedics surgeons we are dedicated to providing compassionate care to our patients. We benefit from the varied knowledge and skills of all of our surgeons enabling us to provide comprehensive orthopedics care and services.
Our Vejthani Orthopedics Center is equipped with modern and effective medical services and facilities provided to meet the needs for patients with spine and other orthopedic problems. Our excellent and effective services includes : patients with broken bones or dislocated joints from accidents, patients with joint inflammation and rheumatoid, patients with slipped disk that puts pressure on the spinal nerve, Children that have bow legs, congenital clubfoot, and/or flat-foot, patients that require microsurgery for knee joint or shoulder joint, patients that require joint replacement surgery in the knee and hip, bone and joint disorder in children, elderly person with compression fracture in the vertebrae (osteoporosis). We are more than assure to you our competitive prices as well as quality guarantee delivered to you.
Our Surgical Team and Orthopedic Specialist
The surgeons, specialist and staffs at Vejthani Orthopedic Center are our greatest assets, committed exclusively to providing you with quality patient care. Our surgeons and specialist are well experienced and expert in spine surgery and rehabilitation, each with the level of proficiency and International recognition. With their long-term of experience surely will make your experience a grateful one.
The Orthopedics Center at Vejthani Hospital in Thailand offers a complete range of diagnostic, treatment and surgical orthopaedic services. The services includes treating fractures and all types of dislocated joints which is caused by accidents, correction of joint and bone deformities which caused by congenital or accidental, sports medicine consultation, arthritis, limb lengthening, treatment of hand deformities, back pain, herniated disc and other musculoskeletal problems. It is equipped with modern facilities to meet the medical needs in diagnosing and treating the customers or patients' medical problems. The physicians are highly knowledgeable and internationally competitive, together with the accommodating nurses, health aides and other hospital staffs serving both native and foreign patients. It is guaranteed that they can give you the best medical treatment while relaxing in a cool ambiance. Vejthani Hospital has JCI (Joint Commission International) accreditation standards for hospital. This means that the medical treatment and service is of top standard designed to improve quality of care delivered to the patients. Feel free to visit our hospital and experience a world class services.
- General orthopaedics
- Fractures and all types of dislocated joints which is caused from accidents or sports
- Sport Medicine consultation
- Injuries or chronic pain from sports
- Arthritis
- Osteoarthritis from old age or other diseases ( visit TJR Center )
- Joint replacement such as knee joint,hip etc. ( visit TJR Center )
- Arthroscopic surgery ( visit TJR Center )
- Correction of bone and joint deformities which is caused from congenital or accidental
- A leg length inequality
- Microscopic surgery
- Hand deformities
- Brachial plexus injuries
- Back pain from work injuries and herniated lumbar disc
Service Hours
Monday - Sunday: 08:00 am - 08:00 pm
Orthopedics Center, Vejthani Hospital, 3rd Floor
Appointments & Inquiries
Phone : +66 (0) 2734-0000 ext. 2298,2299
Fax : +66 (0) 2734-0044
List Doctors
Packages and Promotions
Doctors Information
Special Offers
Subscribe to our newsletter

subset: commoncrawl


text:
News & Events
March 21, 2006 - Scott Gottlieb, MD - Annual Biotechnology Meeting
Speech before
Pacific Northwest Annual Biotechnology Meeting
Remarks by
Scott Gottlieb, MD
Deputy Commissioner for Medical and Scientific Affairs
Food and Drug Administration
March 21, 2006
This text contains Dr. Gottlieb's prepared remarks. It should be used with the understanding that some material may have been added or deleted during actual delivery.
I want to thank you for the opportunity to join you here today.
Tomorrow I will be attending an important event at FDA's regional office here in the Pacific Northwest. As many of you know, FDA is celebrating the 100th Anniversary of the creation of the Food, Drug and Cosmetics Act, the legislation that gave rise to the modern FDA. Tomorrow's event will commemorate that achievement, and the achievements of FDA over the past century as well as those we continue to make under the leadership of Acting FDA Commissioner Dr. Andrew von Eschenbach at enabling a lot of opportunities for consumers to improve their lives.
We will also be celebrating recent achievements, especially the triumph we have all made in recent years toward developing a base of science and technology that puts us on the threshold of a great change in healthcare and medical practice. In fact, when you look back at the last 100 years, when you read the original Food and Drug Act, it's striking to realize all of the progress we have made in biomedicine and in medical practice.
It's striking to see how much medical practice itself has changed as a result of technology and scientific innovation.
One hundred years ago we didn't have antibiotics. We didn't fully understand how germs caused disease. Didn't know what viruses were let alone retroviruses, or prions. We didn't know how to do what are today the most basic surgical operations. It's hard to believe we are only fifty years removed from the central dogma of the double helix.
A remarkable transformation has occurred during the lifetime of those of us in this room, one that depends upon application of the laws of physics and the structural relationship of chemistry on the fundamentals of biology. And it's impossible to divorce that scientific progress, made over the last century, from all of the gains in health and life expectancy and general wellbeing that we've achieved in our lifetime -- not just here in the U.S. but around the world.
And American companies and American research institutions – both public and private -- have led that scientific progress. It's this progress that has enabled a global renaissance in health. And this achievement is perhaps our nation's most important and enduring contribution to the world.
But this progress has not come without its own challenges, without sacrifice, and without its own costs. And it has not been a smooth ride along the way. In fact, even when you look back at that scientific progress and more generally, at the evolution of medicine and medical science since 100 years ago, or from any time in history, I think you see various inflection points, various points of transformation, where things plodded along, as we made small improvements, until medical practice and health and wellbeing more generally underwent major improvements owing to some important discovery that changed the way we approached life science.
This is true whether it was the basic discoveries about human anatomy that opened the door to approaches to surgery, or the advent of modern germ theory and the discovery of bacteria as the basis of disease -- or more recently, the firming of our understanding of the immune system and the advent of both active and passive immune therapies like monoclonal antibodies.
And it is surely true today, as this progress continues, and we stand on the brink of another inflection point – another transformation -- with our growing mastery of the genetic basis of disease through the science of genomics and proteomics.
The Pacific Northwest has been at the vanguard of much of that recent progress.
Washington State alone is home to more than 220 biotech companies; forty-two percent formed in the last five years. And this region is also home to one of the fastest growing public research centers in the world. This biotech industry is founded on and continues to thrive due to the region's world-class research institutions such as the University of Washington, Washington State University, the Oregon Health Sciences University, the Fred Hutchinson Cancer Research Center, the Pacific Northwest Research Institute, the Virginia Mason Research Center, and many others.
Public-private partnership has been important to medical progress and it has been important to the Pacific Northwest. And it is important to our future. And it's this future that I want to talk about today, the steps we need to take working together to enable it, and the steps FDA is taking right now.
While healthcare achievements in past decades have been impressive, I believe, owing to recent scientific advances, there is a lot of medical progress that we're poised to realize in the next decade or two. And this progress may already be showing up at FDA, in the way of many more innovative molecules that we're seeing filed with the agency as part of investigational new drug applications.
But with so many people suffering from diseases today that could be more treatable or even cured in the near future, these new molecules are still taking too long to be turned into practical solutions patients can safely use, and scientific breakthroughs aren't resulting in medical benefits soon enough.
The plain truth is that despite all of our scientific progress in recent decades, the chances that a new molecule will be successfully developed into a safe and effective medicine hasn't changed one bit, and by many measures, it has slipped, even while the cost of developing a single new medicine has nearly tripled in just the last decade. And this has happened even while our investments in research have grown enormously as well, on the order of $120 billion in R&D spending, once you factor in the money spent by the National Institutes of Health as well as private companies and public institutions.
As health care costs continue to rise, it's increasingly important to make sure we're taking steps to address concerns that new medical innovations that can help end suffering and reduce overall healthcare costs are not themselves prices out of development. The plain truth is that we've seen a lot of discoveries made in laboratories in recent years but we're not seeing enough of these discoveries turned into practical benefits for patients. Right now, the number of novel drugs approved by FDA is near an all time low. We're simply not seeing all of the products many people expected from recent scientific advances in genomics and proteomics entering the late stages of development, and the drug development process itself may be one reason why that's so.
So it's clear that we stand at an important moment when it comes to drug discovery. And we have a lot of hard decisions to make together. On the one hand, it's clear we are on the cusp of perhaps another great transformation in medicine. But on the other hand, we have some hard policy decisions that we need to make, and we have to decide whether we are going to have the will and the commitment to make sure that this new science results in practical benefits for patients and isn't unrealized because we made the wrong policy decisions that squandered the vast research industry we have grown up in modern times.
In fact, some suggest right now that the problem rests with the drug industry itself, and that more of the research and development into new drugs should be handled by public institutions like the NIH and academic centers. Now, I don't think basic science institutions would argue that they are equipped to do this kind of translational work, to actually develop drugs, and I don't think it's an either or proposition. The private drug industry has surely benefited from the basic discoveries that are made by public institutions. Now, I think it's fair to say that the growth of a public research base and the NIH in particular has been one of the most successful endeavors our government ever undertook. We set out to establish a base of scientific expertise in order to grow up a modern life sciences sector in this country, and to the benefit of literally tens of millions of people, we have done just that. Because the result is that, seizing on this science base, for profit companies, fueled by the investment capital of millions of individual investors and the incentives offered by our well-developed equity markets, lead the world in chasing the hardest and most expensive medical solutions -- whether it's a new drug based on a completely novel mechanism or a very intricate medical device infused with modern drugs and tissues or something completely novel that we have yet to fully envision.
But if we're going to continue to make progress, and capitalize on a lot of this new scientific work and develop all of the practical medical treatments we need and expect, than I think the distinct roles that the private sector and public research institutions play are going to become even more important, and their unique endeavors and expertise even more discrete and more necessary.
That's because the problem, I believe, is that we've hit a wall when it comes to the science of actually developing new drugs. All of that terrific, highly advanced science that we've developed in the last few decades is resulting in highly innovative new molecules. But once those molecules leave their sophisticated laboratories, they enter a development process where the scientific tools have often been stuck in time for decades or more.
I believe this is a big reason why we're not seeing all the progress we expected from the enormous investments we've made in basic science. And what's happening in drug development is the exact opposite of what has happened in other high technology fields in recent years. In other fields, the tools for developing finished products have undergone dramatic advances, resulting in better products being turned out faster and at a lower cost. Look what has happened to the design or airplanes or even microchips, where advances in the development process itself are largely responsible for the dramatic advances in the finished products that are produced.
But none of this is true when it comes to drug discovery. In drug discovery, the best ideas still bump up against some of the oldest development tools. In drug discovery, all of the work and investment and innovation have gone into the front end, the discovery side of science. Little or no attention has been paid to the middle part of the process, the development part, when drugs are tested and manufactured and turned into medicines.
And the result is that we're not seeing many more medicines. The result is all of that good science on the front end is not coming out the other side. It's getting stuck in the middle. The result is that when it comes to drug development, in too many cases, we're uses tools to evaluate new drugs that were literally developed decades ago – sometimes 50 years ago or more, to test and evaluate new medicines. The same kinds of scientific and process improvements that expand medical practice, making it more precise, more effective and safer can have the same benefits on the way we develop medicines.
Now it's true that modernizing our approach to drug development has not been one of our goals. But that needs to change. And it's going to require a lot of collaboration across public and private entities, because the scope of the scientific work that we need to do is just too large and cross-cutting.
Too often, in the past, we settled for the tried and true ways of doing things, even if better scientific tools were available -- drug developers and FDA preferred familiar approaches. That worked for a while when most of the medicines we were testing worked in similar ways, and were being aimed at similar ailments. But more and more, the new drugs that are being developed are based on completely new scientific approaches such as genomics and proteomics. More and more, new drugs are being targeted to very novel medical indications and they are increasingly bumping up against a scientific development process that isn't sufficiently advanced to evaluate them and move them to the bedside. So the entire process that drug developers often follow is not only too slow and too inefficient, but it's also needlessly expensive.
We need to fix that if we're going to make sure that all of the discoveries that are being made in laboratories, all of the things you read about in the science section of the newspaper, are going to be made available to patients in the form of safe and effective new treatments. And FDA needs to be a part of that, because we're often the ones who set the standards for how that development process unfolds. At FDA, we need to make sure that process is rigorous, safe, and well validated. But also that we're incorporating the most modern scientific tools and approaches, even if it means breaking with something tried and true if we have clearly identified a new scientific approach that is better. With so many people suffering right now from diseases that may be treatable or even cured in the near future, we can't wait many more years, and spend millions and even billions of dollars to develop each and every medicine, simply because our process for doing so isn't incorporating the most modern scientific tools and approaches and therefore takes too long and costs too much and is too prone to failure.
The good news is that I think there are more opportunities than ever to improve the development process. With the reauthorization of the prescription drug user fee act this year, we have the opportunity to continue to bring modern management tools and approaches to the process for evaluating new molecules to make sure they are safe and effective. And with FDA's new critical path initiative, we have the opportunity to modernize the science of drug development itself -- the science of how we actually go about evaluating new molecules.
And so at FDA, we have set out on two simultaneous efforts to confront these challenges. The first effort is to modernize the scientific tools we use to evaluate new drugs. And the second effort is to continue to make improvements in the process for regulating new medicines to make sure that we're incorporating the best management approaches, the best information technology, and the best quality systems and review processes to perform our daily mission.
To tackle the first challenge, under the leadership of Dr. Janet Woodcock, we have undertaken a new initiative to modernize the science of drug regulation as part of our Critical Path initiative. Critical path is a broad initiative at FDA, involving all of our medical centers. The effort is aimed at catalyzing the creation of a new generation of scientific tools to enable product sponsors to better predict and evaluate the safety and effectiveness of candidate products; to make product development less risky and more efficient; and to enable individualization of therapy to improve effectiveness and avoid side effects.
Our goal is to translate the science developed under this initiative into FDA guidance to scientists and product manufacturers in order to clarify the regulatory path for modernizing approaches to bringing products to market. Under Critical Path, we are working on long-term science development as well as near term improvements and modernizations in our own regulatory procedures to accommodate new scientific tools and approaches.
For example, we are launching a clinical trial collaboration to validate the use of positron emission tomography imaging as a surrogate endpoint for cancer therapies, in partnership with the National Cancer Institute, the Centers for Medicaid and Medicare Services and other partners. We hope to expand this collaboration to include additional imaging technologies. We also recently launched a new biomarker qualification program in collaboration with the National Institutes of Health. And we announced other new initiatives aimed at improvement the scientific process for evaluating new drugs, such as a safe framework for conducting early studies with micro doses, as well as a safe harbor for the submission of pharmacogenomics data, which we hope to soon extend to other kinds of data submissions such as proteomic data.
At the same time, we are developing regulatory guidance for incorporating these new scientific tools into the development process. One such guidance, which should be out in draft form this year, addresses how product developers can seek approval for a new drug and a diagnostic test for guiding the targeted use of that therapy, all within the same registration trial.
But to do these things, we're going to need your help. As I said, the biggest challenge is that a lot of the scientific work we're trying to do under our critical path is too broad to be done by any one institution or company. And so its going to require a lot of partnerships across both private and public entities and a lot of it is going to require the help of leading research institutions like those here in the Pacific Northwest. We're only going to be able to get these things done, and advance the science around drug development, if we all work together.
While we take these steps to modernize the scientific tools that are used during drug development, we are also mindful to continue to take steps to modernize our own processes and approaches so that we are adopting modern management approaches and so that new scientific tools can become effectively integrated into the registration process. The original vision behind the PDUFA legislation was that it would enable FDA to incorporate modern management approaches into how it went about its scientific work. The legislation has been a significant success in achieving that goal, but there is still more we want to do and more we can do. And so while the new reauthorization of PDUFA could provide another important opportunity to bring focus and resources on making additional improvements in the drug review process, there are many things we are doing right now under the leadership of Dr. Steven Galson, the head of our Center for Drugs, Dr. Jesse Goodman, the head of our Center for Biologics, and many others.
One way we can do this, for example, is to promulgate guidance on how scientists can use these new tools as part of the drug development process. We also want to continue to take steps to modernize our own internal approaches to evaluating the information we receive, and setting regulatory standards, whether it is through process improvements in our own work, through quality systems we adopt, or through technological improvements such as the incorporation of information technology to help us better evaluate the information we receive.
To these ends, we recently announced a new commitment by the FDA to improve the process for collecting medical information as part of the so-called phase four trials or "post marketing commitments" drug developers often undertake after drugs are approved. We will also soon be announcing a quality system around how we conduct meetings with sponsors and how we generate meeting minutes. The meetings we take with sponsors, especially early in the development process, have become an invaluable part of creating good development programs for new molecules.
A recent report that we commissioned by the consulting firm Booz Allen, to examine the root cause of why many molecules fail in development or need to undergo multiple cycles of review before they are eventually approved, found that sponsors that have early communications with FDA, seeking advice about their development programs, and sponsors that follow the advice they receive, stand a higher chance of success with their molecules. In fact, all things considered, early and effective consultation was one of the single best predictors of success in the review process. So we plan to take additional steps to make sure these consultations are as effective as possible. We will be finalizing soon a guidance document that deals with best practices for how these meetings are conducted, and how we can make sure that we are making the most of these opportunities to give feedback to sponsors on their development programs. We plan to issue this guidance in June.
We will also be undertaking an internal initiative to create process and procedural improvements in the way we generate written records from these meetings.
Something like minutes from a meeting sounds like the kind of work that goes on every day in ordinary business enterprises, but at FDA these minutes can sometimes be very detailed and intricate. We know that these meeting minutes – done right -- can be an important tool to help sponsors get good guidance on how to design appropriate trials to demonstrate safety and effectiveness. So we want to make sure we're maximizing the value of this important information tool, to improve the consistency and the transparency of the review process.
The initiative we're undertaking, with the help of outside experts, will evaluate current practices for ensuring accurate, quality meeting minutes content and format used in the drug and biologics centers, and it will recommend best practices for how to write clear, concise meeting minutes that accurately reflect meeting outcomes. We will also be providing in-depth training for staff within both of our centers on developing meeting minutes with good content and format. The professional staff at FDA devotes significant resources of time and talent to these meetings and continues to work to make sure they are a valuable part of the scientific exchange that takes place during the development process.
These are just a few examples, I spoke about today, of how we want to use modern science and modern management tools to make sure we're taking the most effective approach to determining the safety and effectiveness of new medical products, and that we're doing all of these things in an efficient way. Taking new ideas from the notebook to the market requires huge investments in research and development. This is a risky process, and risk is the enemy of investment. To continue to make progress, we have to do all we can to make sure that process is as modern, and efficient, and as effective as science allows.
The bottom line is this: There are many opportunities to improve our current process for drug development – improvements that could provide greater efficiencies to the development process, and even more important, improve our ability to determine the safety and effectiveness of a new medicine much earlier, and perhaps with less cost. Working together, by harnessing modern scientific tools and smarter approaches to our work, we can improve the development process, making it more efficient and more effective, so that innovative new medicines can get to the patients who need them. Thank you.


text:
N.C. may compensate sterilization victims
ASHEVILLE, N.C. – North Carolina is moving toward becoming the first state to compensate victims of an involuntary sterilization program that tried to filter out poor people deemed mentally or otherwise unfit to produce offspring.
The practice was declared legal by the U.S. Supreme Court in 1927 but tapered off in most states during World War II as word of Nazi genocide and sterilization began to spread.
North Carolina's program was unusual because it continued for so long, according to Charmaine Fuller Cooper, the executive director of the N.C. Justice for Sterilization Victims Foundation. Most victims in the state were sterilized from 1946 to 1968.
State lawmakers held a public hearing in Raleigh this week, then voted to send the reparations bill on to the finance committee. The bill has bipartisan support.
"This is not a perfect bill," said sponsor Rep. Larry Womble, a Democrat. "But it is a bill that separates North Carolina from the rest of the world. This is a proud day."
Top states
More than 60,000 people were forced or coerced into sterilization procedures in the USA from about 1907 to 1974. Programs in about 30 states largely targeted the poor and mentally ill. Top five states for sterilizations performed:
Source: Lutz Kaelber, associate professor of sociology, University of Vermont
Democratic Gov. Bev Perdue's budget has $10 million set aside to compensate living victims with $50,000 payments. The victims would have to come forward by the end of 2015. The plan is one of the few things on which the outgoing governor and Republican-controlled General Assembly appear to agree.
"Get it over with and have it done so they can enjoy it before they die," Republican Rep. Paul Stam said during this week's hearing.
More than 30 other states had similar eugenics programs, said Lutz Kaelber, a professor at the University of Vermont who has studied the practice. There were about 60,000 victims nationwide, including more than 20,000 in California, Kaelber's data show. He said he has not heard of any other state considering compensation.
Reparations are intended for the estimated 2,000 living victims in North Carolina. Womble cried as he told the committee this week that no other state is considering making reparations. Republican Rep. George Cleveland said North Carolina, like other states, has apologized and should not make reparations.
"People today pay for something that happened in the past," he said. "I don't believe it's correct."
North Carolina relies on self-reporting. So far, 132 victims have been identified, Fuller Cooper said. The reason for the self-reporting policy is to minimize harm, she said. Sending a notification letter to a woman who might have been sterilized could mean unintentionally exposing a horrible part of her life to her family, she said. A victim may authorize others to report sterilization.
Fuller Cooper said she is optimistic that lawmakers will approve the legislation during the government's short session this summer.
Ostendorff also reports for the Asheville (N.C.) Citizen-Times.
Posted | Updated


text:
Badass Businesswomen 3-Year Anniversary
Badass Businesswomen
Friday, February 22, 2013 from 7:00 PM to 10:00 PM (EST)
Who's Going
San Francisco, California
London, United Kingdom
Florence, Italy
Event Details
BIG NEWS! Absolut is officially onboard as the spirits sponsor of the Feb22 party!!! They are bringing 144 bottles of "Absolut Tune", a new fusion of Vodka and crisp sparkling wine. OMG it sounds so good...and the packaging of the bottle is outrageous! Check out the picture below and start salivating. lol
BOYS ALLOWED: Yes! Men allowed! Some of you boys will be lucky enough to spend a luscious evening mingling with Miami's babelicious Badass posse. But seriously, RSVP fast.
TICKETS SELLING OUT FAST: We ran out of tickets last week even faster than we anticipated. Our amazing host, IronFlower Fitness came to the rescue and opened up an entire new room so we can give away more tickets!!! Thanks IronFlower!!! We've now raised the ticket max up to 300, but we WON'T BUDGE after that. Either you get them or you don't. I won't be at the door to vouch for you. No crying at the door when my team won't let you in. RSVP here.
TO THE CURRENT RSVP LIST: These parties are HOT. Super HOT. You're lucky to have tickets. Can't wait to see you all! Once a year isn't often enough to have us all in the same room all at the same time. ;)
When & Where
IronFlower Fitness
7300 Biscayne Boulevard
Friday, February 22, 2013 from 7:00 PM to 10:00 PM (EST)
Add to my calendar
Badass Businesswomen
Being a badass is a state of mind, regardless of one's gender.
Unfortunately, a business woman who is strong-willed, ambitious and clear about her goals is too often labeled a "bitch." Being an edgy and vocal woman is not always celebrated in the business environment.
Being a card-carrying Badass Business Woman does not merely announce and unleash your inner badass. Consider us a tribe – coming together, challenging and mentoring one another in today's male-oriented business world.
Being a Badass Business Woman is not about running stiletto-clad circles around men. It's about gracefully striding forward in the business world with a radiant strength and confident dexterity that is uniquely female.
Are YOU one of us?


text:
What is in this article?:
- Automated Clamping Pays Off, Even for Small Batches
- Spindles Drive Clamping
- Retrofitting Options
- Reducing clamping, set-up times
- Comprehensive expertise in control technology
- Adjuste torque, speed, waiting time, rotation direction -- individually
- Vital communications interfaces
- Minimizing service, maintenance costs
Roemheld's clamping processes exhibited at EMO 2013.
Robotic automation is increasingly common in the production of high-value and high-quality workpieces. But, such set-ups require a clamping device to hold a component in place, ready for machining. However, when using a conventional palette storage system the machining steps can be carried out only in a fully automated process. Then, production flow is held up if components need to be turned, or if clamping jaws (or even entire fixtures) need to be changed. Roemheld, a specialty developer of clamping systems (and other automation machinery) has an alternative.
Roemheld technicians and design engineers develop customer-specific solutions, and their new clamping development involved some collaboration with Deprag Schulz GmbH — which also develops automation concepts, involving screwdriving technology and air motors, as well as more complex automation programs.
At EMO 2013, Guido Born, Roemheld's product manager for the Workpiece Clamping System product line,described some new solutions for automated machining, solutions that can be implemented sustainably even for very small of batches of production.
Q: Over the past 20 years international machine tools usage has risen by 70%. Half of all such machines come from Europe alone and are supplied to more than 70 countries. These figures indicate an opportunity for suppliers of production technology, but in the global competition who really is ahead?
The theme of EMO 2013 was "Intelligence in Production," so it required intelligent solutions for production technology that are sustainable into the future, so that they can cope with the enormous pressures on costs and the ever-increasing demands for efficiency and environmental sustainability. I think that we in Europe have a certain leadership role to play here in all of these aspects, and that we are ahead of the global competition.
What does that mean for your particular product area, clamping technology?
Born:We are constantly striving to reduce clamping and set-up times for our customers in the machining of their workpieces. Shorter clamping and set-up times, longer machine runtimes, greater accuracy of workpiece machining and precise repeatability of every clamping force and positioning routine are the most significant advantages of this automation solution and they were a clear focus of our design work.
What effect do the new clamping systems have?
Born:Every step of the process - from inserting the workpiece into the clamping device, the machining process and removing the workpiece is automated. If workpieces need to be turned during machining, and the clamping jaws require changing, or the clamping area altered, these processes can also be automated. It means that several clampings and different work processes can be carried out without manual intervention.
To what sort of workpieces are the new automation solutions suited?
Born:Our clamping solutions are suitable for components of varying sizes, dimensions and geometries, enabling machining on up to six sides with no operator intervention. Of course the restrictions on dimensions and mass are imposed by the available machine space and the type of freely selected robot used.


text:
Economy too weak to slow bonds
WASHINGTON — The economy may not be strong enough for the Federal Reserve to slow its bond purchases this year.
That's the takeaway from economists after the government cut its estimate on Wednesday of growth in the January-March quarter to a 1.8 percent annual rate, sharply below its previous estimate of a 2.4 percent rate. The main reason: Consumers spent less than previously thought.
Most economists think growth will remain low as consumers and businesses continue to adjust to federal spending cuts and higher taxes. Growth is expected to reach an annual rate of only about 2 percent in the April-June quarter. Even if the economy improves slightly, it would be hard to meet the Fed's forecast of 2.3 percent to 2.6 percent growth for 2013.
Chairman Ben Bernanke rattled investors last week when he said the Fed will likely slow its bond buying this year if the economy continues to strengthen. The bond purchases have helped keep interest rates low. Bernanke added that if the economy weakens, the Fed won't hesitate to delay its pullback or even step up its bond purchases again.
Jennifer Lee, senior economist at BMO Capital Markets, said that if the April-June quarter proves tepid, the Fed will be looking at three straight quarters of subpar growth.
"The Fed won't taper (its bond purchases) under these conditions," Lee said. "They need convincing signs of a pickup."
Joel Naroff, chief economist at Naroff Economic Advisers, said he suspects the Fed will wait until next year to slow its bond buying. Like most economists, Naroff thinks growth will pick up in the October-December quarter and strengthen in 2014.
"If the Fed doesn't take notice of this revision to growth, they would run the risk of being perceived as largely clueless about the economy," Naroff said.
Stocks surged on Wednesday, a sign that many investors also suspect the economy may prove too weak for the Fed to begin scaling back its stimulus later this year.
The Dow Jones industrial average closed up nearly 150 points. Broader stock indexes also surged.
Most of the revision to last quarter's growth was because of a decline in consumer spending to an annual rate of 2.6 percent. Though that pace is the fastest in two years, it's sharply below the 3.4 percent rate previously estimated.
A key factor was weaker spending on services, such as travel, legal services, health care and utilities. Spending on long-lasting manufactured goods, considered a barometer of consumers' confidence in the economy, was stronger than previously estimated.
Some economists said the lower estimate suggests that an increase in Social Security taxes that took effect this year might be squeezing consumers more than expected. The tax increase has reduced take-home pay for most Americans. A person earning $50,000 a year has roughly $1,000 less to spend. A high-earning couple has up to $4,500 less.
"There was still acceleration in the growth of consumer spending — just not as much," said Paul Edelstein, director of financial services at IHS Global Insight.
The government's revisions also pointed to less export growth and weaker business investment spending, mainly because of less spending on buildings than previously estimated.


text:
"Through Sunnybrook's leading innovation and real-life training, I have been fortunate to gain a broader international perspective, enhancing my knowledge and education. For me, it's about gaining the most current research and expertise to provide the best patient care, all in an effort to advance the science of medicine.
THOUGH HE GREW UP in Sydney, Australia, Dr. Andrew Lansdown's favourite thing about Canada is the weather. An avid fan of winter sports, he excitedly watches the forecast for news of massive snowfalls – and it's this same sense of adventure that brought him to Sunnybrook.
As a clinical fellow with the Department of Anaesthesia, he is halfway through a one-year fellowship in regional anaesthesia, which involves delivering local anaesthesia to block large areas of sensation.
"It's been just what I'd hoped it would be: it's been perfect," Dr. Lansdown says of his Sunnybrook experience, adding that he's already recommending it to others.
"What I've tried to do is develop a greater theoretical and practical knowledge, so I can take it back home as a better teacher and educator." Being exposed to a high volume of nerve-block procedures has helped him hone his skills and gain the necessary confidence to take his new expertise back to Australia.
Under the supervision of Dr. Colin McCartney, he has appreciated the effort of the entire Department of Anaesthesia staff to provide education and guidance. He admires his Canadian colleagues for their ability to push themselves professionally beyond their everyday clinical roles, through side projects such as participation in research, councils and committees.
"Everyone has a special talent here, their own niche that they're really passionate about and working on; it makes for great teamwork," he says.
Unlike most hospitals in Sydney, Dr. Lansdown says, Sunnybrook provides fellowship opportunities for international staff. Dr. Lansdown's keen interest in gaining a diverse professional experience, as well as fulfilling his sense of adventure, brought him to Sunnybrook. But ultimately, it is his own medical expertise and unique global perspective that enrich Sunnybrook's caring practices, and no doubt will better the entire hospital community.
FROM GUITAR RHYTHMS to circadian rhythms, Dr. Georg Bjarnason has come a long way in his life and career. In 1965, he was just a 14-year-old guitarist when his band The Falkons opened for rock legends The Kinks in Dr. Bjarnason's native Iceland.
"It was amazing," he recalls. "I did not realize the significance of it until after the fact."
By age 17, he was already a gliding instructor, flying engineless over the local mountainside. He says that the trick to flying safely was staying nimble and adapting to the rhythms of nature's air currents.
After earning his medical degree in Iceland, he came to Canada in 1983 to complete his training in internal medicine and medical oncology. Twenty years later, he's making his biggest mark yet as a medical oncologist with Sunnybrook's Odette Cancer Centre, an expert on kidney cancer and one of Canada's leading researchers in biological rhythms, or chronobiology.
Here, the responsive approach he learned from flying continues to guide his research in understanding the human body to better individualize cancer treatment.
All living organisms have a 24-hour biological clock or circadian rhythm. Dr. Bjarnason has studied these rhythms and the genes that control important biological processes such as cell cycle, and has found important gender differences in genes at different times of the day that may explain gender differences in the activity and side-effects of most drugs.
Chronotherapy (therapy based on an individual's circadian rhythm) may help doctors improve drug therapies and minimize side-effects. "Chronotherapy will not cure cancer but may make the most of the few active drugs we have," says Dr. Bjarnason.
The senior scientist at Sunnybrook Research Institute has studied timing of radiotherapy in patients with head and neck cancer and timing of chemotherapy in patients with colorectal cancer. He and colleagues have confirmed that abnormal sleep patterns are associated with poorer survival in cancer patients.Report Typo/Error
Follow us on Twitter: @Globe_Health


text:
Customers have installed this add-on in at least 12 active instances.
by Hannes Marthfor JIRA Server 6.4.11 - 6.4.14
This add-on isn't formally supported.
This add-on isn't formally supported.
Get it nowFree add-on
email validation text field
email validation text field
This custom field accepts only an email address.
In-browser validation is available for HTML5 compatible browsers.
Absolutely no configuration required. Zero. Nada.
More details
There are no additional details.
User reviews(2)Sign in to write a review
Support is not available for this add-on.
Vendor support resources
See existing Q&A in Atlassian CommunityAsk a question in the Atlassian Community
Atlassian-hosted discussions connect you to other customers who use this add-on.
Version 1.0.1 • JIRA Server 6.4.11 - 6.4.14 • Released 2015-08-27
Initial Release
- Log into your JIRA instance as an admin.
- Click the admin dropdown and choose Add-ons. The Manage add-ons screen loads.
- Click Find new add-ons from the left-hand side of the page.
- Locate Custom Field: Email via search. Results include add-on versions compatible with your JIRA instance.
- Click Install to download and install your add-on.
- You're all set! Click Close in the Installed and ready to go dialog.


text:
RADDATZ: Senator Paul is with us now. Senator, thanks for joining us. Did the president address all your concerns about drones?
PAUL: Well I was pleased with his words, and I was pleased with the -- that he did respond to this. However, there still is a question in my mind of what he thinks, due process is? You know, due process to most of us is a court of law, it's a trial by a jury. And right now their process is him looking at some flashcards and a PowerPoint presentation on "Terror Tuesdays" in the White House. For a lot of us, that's not really due process.
RADDATZ: Well one of the things the president did say is there would be rules for the drone strikes. He said targets pose a continuing imminent threat, only near certainty no civilians hurt or killed and not used to punish terrorists. That seems like a change?
PAUL: Yeah, but a lot of -- a lot of what's very important to myself and others is what the law says, and how you should approach this. For example, it's not good enough for us that he's not using a power. We want him to assert that he won't. That he doesn't have the power. For example, last year we passed legislation that I voted against, and may civil libertarians opposed, and that's detaining citizens indefinitely without a trial, and sending them to Guantanamo Bay. Now the president said he won't use that power. But we think a president who really believes in civil liberties, would have vetoed the bill, and not signed the bill.
RADDATZ: All right. I -- I want to go back to the drone strikes for a moment. They also revealed this week for the first time publicly, that four Americans had been killed in drone strikes, including Anwar al-Awlaki in Yemen. Should he have not been targeted by a drone?
PAUL: My preference would be that when an American commits treason, particularly if they're not actively involved in a battle, if you're an American fighting with the Taliban, you're going to be shot with no due process.
RADDATZ: But -- but...
PAUL: That's what happened...
RADDATZ: ...how do you go after someone like...
PAUL: ...and if you're conspiring against America...
RADDATZ: ...if you can't get him?
PAUL: Let me -- let me finish my point. Let me finish -- let me finish my point so I can -- we can have a discussion. But, if you are conspiring to attack America and you are a traitor? I would try you for treason. If you don't come home for the trial, I would try you in absentia, and then the death penalty has repeatedly been used throughout our history for treason, but a judge looks at evidence. And that's something that separates us from the rest of the world, is that we adjudicate things by taking it to an independent body who is not politically motivated, or elected.
RADDATZ: Let -- let's move back to Guantanamo. The president did speak about closing it. No specifics though. Do you think it should be closed?
PAUL: No. I think it's become a symbol of something though, and I think things should change. For example, I think the people being held there are bad people. What I would do though is accuse them, charge them, and try them in military commissions, or trials, or tribunals. And I think that would go a long way toward showing the world that we're not going to hold them without charge forever.
RADDATZ: I want to move on to the IRS. Do you believe that this was limited to the Tea Party? Targeting the Tea Party? Or do you believe there were other groups as well, targeted?
PAUL: You know, I don't know. I don't know whether people were targeted for conservative religious values, or just conservative political values, and sometimes there's an overlap. I think we have to get to the bottom of this. I think the constellation of these three scandals ongoing, really takes away from the president's moral authority to lead the nation. Nobody questions his legal authority, but I think he's really losing the moral authority to lead this nation. And he really needs to put a stop to this. I don't care whether you're a Republican or a Democrat, nobody likes to see the opposite party punishing you for your political beliefs.
RADDATZ: You -- you...
PAUL: ...using the power in government to do so.
RADDATZ: ...you've called for a special counsel on the IRS. Do you see any evidence that a crime has been committed thus far?
PAUL: I don't think we know so far. The main woman from the IRS that's involved, has taken the Fifth Amendment. She's no longer cooperating. So I have called for her suspension. The president did respond to that, and he has suspended her. However, he's still paying her. So I don't want that to go on forever. I think there needs to be a speedy resolution to this. And I think the president is in danger of losing his moral authority to lead the nation if we don't get to a resolution. Now he said he's going to listen to his commissioner, new IRS commissioner in 30 days.
Well, the investigation's been going on over a year now, so I would think it wouldn't take very long. If he goes beyond 30 days and if no one is fired over this? I -- I really think it's going to be trouble for him trying to lead in the next four years.
RADDATZ: But let -- let's move to immigration. Would you support the bill, the Senate bill that made it through committee this week?
PAUL: I support immigration reform. At this time, I think the bill needs to strengthen border security. It also needs to expand work visas. The main problem with illegal immigration is that we don't have enough legal immigration. This bill, because it was negotiated with the unions, actually lowers the numbers for work visas. That's exactly the wrong direction to go. So I will support a bill that fixes it, and I do want to support a bill. I've talked to the authors of it. If they work with me on my amendment, which is called Trust But Verify, there is a very good chance I can vote for it. But it has to be a better bill.
RADDATZ: And a pathway to citizenship?
PAUL: I would say no new pathway. And I'm a little concerned that some will interpret it, and it may will be a new pathway because they've created a new visa category. My preference would be to change the law that says you can't simultaneously be in the work visa line, and in the pathway to come to this country. As long as somebody who has a work visa is treated the same as a new person in Mexico City, who wants to get in line tomorrow, I don't have a problem getting in the normal line. I just don't want to create a new line, or give a new preference to people who are here undocumented. But I am all in favor of letting undocumented workers become documented workers, and finding a place for them.
RADDATZ: Thank you so much for joining us, Senator Paul.
Source: http://abcnews.go.com/Politics/week-transcript-sen-rand-paul/story?id=19245152#.Uajgu6CW1Kg


text:
Click on a thumbnail to go to Google Books.
John F. Kennedy
by Alan Brinkley
No current Talk conversations about this book.
No reviews
References to this work on external resources.
Wikipedia in English
Amazon.com Product Description (ISBN 0805083499, Hardcover)
The young president who brought vigor and glamour to the White House while he confronted cold war crises abroad and calls for social change at home
John Fitzgerald Kennedy was a new kind of president. He redefined how Americans came to see the nation's chief executive. He was forty-three when he was inaugurated in 1961—the youngest man ever elected to the office—and he personified what he called the "New Frontier" as the United States entered the 1960s.
But as Alan Brinkley shows in this incisive and lively assessment, the reality of Kennedy's achievements was much more complex than the legend. His brief presidency encountered significant failures—among them the Bay of Pigs fiasco, which cast its shadow on nearly every national-security decision that followed. But Kennedy also had successes, among them the Cuban Missile Crisis and his belated but powerful stand against segregation.
Kennedy seemed to live on a knife's edge, moving from one crisis to another—Cuba, Laos, Berlin, Vietnam, Mississippi, Georgia, and Alabama. His controversial public life mirrored his hidden private life. He took risks that would seem reckless and even foolhardy when they emerged from secrecy years later.
Kennedy's life, and his violent and sudden death, reshaped our view of the presidency. Brinkley gives us a full picture of the man, his times, and his enduring legacy.
(retrieved from Amazon Thu, 12 Mar 2015 18:04:30 -0400)
Analyzes the contrast between Kennedy's achievements and his legend, tracing the successes and failures of such events as the Bay of Pigs and the Cuban Missile Crisis while exploring the ways in which he reshaped views of the presidency.
Amazon Kindle (0 editions)
Audible (0 editions)
CD Audiobook (0 editions)
Project Gutenberg (0 editions)
Google Books — Loading...
Is this you?
Become a LibraryThing Author.


text:
Save 76%
Only $1.66 per issue!
Revolver Magazine
Subscribe today Save up to 76%!Subscribe Now!
Free Newsletter
Sign up to get The World's Loudest Newsletter! Revolvermag Daily Shred! Sign Up Now!STORE
Alice Cooper. Photo by Jimmy Hubbard
About the Revolver Golden Gods Awards:
Each year, Revolver throws the premiere U.S. hard rock and metal awards show, the Revolver Golden Gods. In its fifth year, the show has featured appearances by Marilyn Manson with special guest Johnny Depp,
Ozzy Osbourne, Metallica, Mötley Crüe, Dave Grohl, Slash, Rob Zombie, Lemmy Kilmister, Rob Halford, Dave Mustaine, William Shatner, Sebastian Bach, Alice Cooper, Kat Von D, and many others.
Visit Revolver Golden Gods on Facebook here.


text:
Accounting & Tax
You are here: Home : Topics A-Z : Accounting & Tax
Follow this topic
- Subscribe to our Accounting & Tax RSS feed
Watchdogs Put Closer Eye on Broker-Dealer Accounting
Regulators like the FINRA are taking a closer look at broker-dealers just as accounting missteps are on the rise. May 10, 2012
Averting Revenue-Recognition Angst
FASB and the IASB seek to allay worries over new rules for booking revenue. April 15, 2012
Online Retailers Feel the Heat
States are pressuring online retailers to collect sales taxes, and a federal statute may not be far behind. April 15, 2012
For Consumer Products Makers, Sales Growth Spurs Share Prices
In the face of lackluster consumer spending growth, consumer products companies created strong value for shareholders. February 1, 2012
Related White Papers
Business Solutions Center


text:
An Ogden man involved in Monday rollover accident on Interstate 80 in Summit County has died of his injuries.
Kathy Wilets, a spokeswoman for University Hospital in Salt Lake City, confirmed Wednesday that Travis Crane, 28, had passed away on Tuesday.
Crane was driving west near Echo Reservoir about 8:15 p.m. Monday when his vehicle rolled four times, coming to a rest in the left lane, the Utah Highway Patrol said.
No other injuries were reported.


text:
Barnard News
Barnard College featured in May Vanity Fair.
Last week, Associate Professor of History Nara Milanich penned a New York Times letter to the editor in response to an article on mistaken paternity (Link to article). Prof. Milanich, who is currently researching a book about the topic, The Birth of Uncertainty: A Global History of the Paternity Test, is under contract with Harvard University Press.
Artist gifts her foundational works to the Barnard Archives
Séverine Autesserre, Associate Professor of Political Science, was awarded a 2016 Andrew Carnegie Fellowship.
The Wall Street Journal recently reviewed Professor Janna Levin's new book, Black Hole Blues and Other Songs from Outer Space.
The John Simon Guggenheim Memorial Foundation has awarded Rebecca Jordan-Young, Associate Professor and Chair of Women's, Gender, and Sexuality Studies at Barnard College, one of 175 fellowships given this year for achievement and exceptional promise.
The New York Times recently reviewed Miller's Valley, a coming-of-age story about Mimi Miller, by Pulitzer Prize-winning journalist and bestselling author Anna Quindlen '74


text:
Open Call
Call for Nominations
Dental Hygiene Review Committee Members
Commission on Dental Accreditation (CODA)
The American Dental Hygienists' Association is seeking to identify qualified individuals to fill upcoming vacancies for one dental hygiene educator and one dental hygiene practitioner on the Dental Hygiene Education Review Committee of the American Dental Association Commission on Dental Accreditation (CODA).
Overview of Responsibilities:
Review Committee members are appointed for one four-year term beginning and ending in October. All Review Committee meetings are conducted approximately three weeks prior to the Commission meetings and the meeting duration can be up to two days in length. The newly appointed representatives will attend his/her first Review Committee meeting in January 2015. Review Committee members are responsible for the review of all policy matters, site visit reports, progress reports, applications for accreditation and special reports on accredited programs. Each Review Committee's comments and recommendations on policy matters and accreditation status are included in a report, which is submitted to the Commission for final action.
As a member of a Review Committee, she/he will be required to make a significant time commitment. Review Committee members serve as consultants to the Commission and are required to complete the Web-based Site Visitor Training prior to serving on the committee. The self-paced instructional manual on the Commission's policies, procedures and Standards takes approximately 6 to 8 hours to complete. Review Committee members will also be required to become familiar with the CODA Training Manual and participate in a full day of training at ADA headquarters in December 2014. Duties may include participation in site visits and ad hoc committees, in addition to review committee responsibilities. Additionally, in order to facilitate committee activities, committee members are expected to be accessible and able to communicate by fax, electronic mail and the Commission's web-based communication tools.
CODA Review Committee Nominations Criteria
All Nominees:
- Ability to commit to one 4-year term
- Willingness to commit 5-10 days per year to Review Committee activities, including training, comprehensive review of print and electronically delivered materials and travel to CODA headquarters
- Ability to evaluate an educational program objectively in terms of such broad areas as curriculum, faculty, facilities, student evaluation and outcomes assessment
- Stated willingness to complete review committee member training
- Adequate time for comprehensive review of program materials and for travel during the winter and summer meetings
- Stated willingness to abide by the Association's and Commission's policies related to confidentiality; conflict of interest; operational guidelines; simultaneous service; and professional conduct and prohibition against harassment
- Ability to conduct business through electronic means (email, CODA Web Sites)
- Active member of the American Dental Association, where applicable
Educator Nominees:
- Commitment to dental, advanced dental and/or allied dental education
- Active involvement in a dental or dental-related accredited program as a full- or part-time faculty member
- Subject matter experts must have formal education and be credentialed in the applicable discipline
- Prior or current experience as a Commission consultant/site visitor
Practitioner Nominees:
- Commitment to quality dental, advanced dental and/or allied dental education
- Prior or current experience as a practitioner
- Must have formal education and appropriate credential in the applicable discipline
Individuals who meet the minimum qualifications stated above must submit a CODA Review Committee Nomination Form (available for download) electronically to ADHA: firstname.lastname@example.com no later than Wednesday, April 9, 2014.


text:
Thanks to a schedule that didn't call for them to play in the first 60-plus games, the Jazz never saw the Washington Wizards team of Gilbert Arenas, Antawn Jamison and Caron Butler that made all the wrong headlines in the NBA this season.
By the time they arrived at EnergySolutions Arena for Monday's game, the Wizards' season long ago had been lost to guns, guilty pleas and recklessness, leaving Andray Blatche, Al Thornton, Mike Miller and others to pick up the pieces.
The Jazz took full advantage of a team in free fall, dismantling Washington 65-35 in the middle two quarters on the way to a 112-89 thrashing, leading by as many as 34 points in sending the Wizards to their eighth consecutive loss.
"It's tough on this team with all the stuff you can imagine that they've gone through and they're still playing," Jazz coach Jerry Sloan said of the Wizards. "They've had a lot of tough things to overcome but they're trying to put their team back together."
Carlos Boozer totaled 23 points, Deron Williams had 17 points and 11 assists and Mehmet Okur delivered 14 points playing through a bad back. All 10 Jazz players in uniform scored, including a season-high 15 from Sundiata Gaines.
"We're not going to take any more teams lightly," Boozer said. "We did a bad job of that earlier on in the season where we would get up for the good games or the tough matchups and we wouldn't be up for the teams we're 'supposed to beat,' quote unquote."
After falling at Milwaukee and Oklahoma City to close their four-game trip, the Jazz stopped their losing streak cold. "I didn't know what kind of energy we would have," Sloan said. "We played five games in seven days and it was good to see our energy level real high."
The Wizards shot 30 percent through three quarters and went 3-for-22 in the third quarter. More than who was in the lineup for Washington, though, what made an impression on the Jazz was who no longer was with them.
"It's weird not to see those guys out there for that team," Boozer said. "We've seen them for so many years, Antawn having big games, Gilbert having big games, Caron having big games. Now you're getting guys other opportunities that haven't been able to play."
The Wizards' season effectively ended Dec. 21 when Arenas and Javaris Crittenton brandished guns in a locker-room confrontation. The resulting fallout consumed the NBA, with the two suspended for the season by commissioner David Stern in January.
After trading Jamison and Butler last month, the Wizards attempted to fast-track their rebuilding process. Their starting five Monday featured Blatche, Thornton, Miller, JaVale McGee and Shaun Livingston. Blatche led with 24 points while Miller had 14.
"It's good to come in and a put a team like this away," said Williams, who wore a padded compression shirt for his ailing shoulder and fell hard on his back trying to drive for a layup in the closing seconds of the third quarter.
"You always see the teams that aren't in the playoffs, they play free, they have no worries. For us to come out and play the way we did tonight, it was good, especially on the second end of a back-to-back."
Okur returned after sitting out Sunday in Oklahoma City with back spasms and dunked off a C.J. Miles' pass only 15 seconds in. He ran for a layup on the break, hit a three-pointer and blocked two Thornton shots all in the first quarter.
The Jazz turned defense into offense twice in the opening 12 minutes. Wesley Matthews and Williams hounded Randy Foye into a turnover with Matthews hitting Williams with a behind-the-back pass on the break for a layup.
Boozer and Williams returned for the final 5:36 of the second quarter and pushed the Jazz to a 59-45 halftime lead. Boozer had a follow-up dunk, flashed open at the foul line and blew past McGee for a layup and delivered a three-point play on Blatche.
The Jazz stretched their lead to 34 in the third quarter as Williams flipped between-the-legs and no-look passes to Okur for long jumpers. Boozer had a three-point play and Williams drove for a three-point play after Blatche dunked and was called for a taunting technical.
"Those are three All-Stars," Williams said of the missing Arenas, Jamison and Butler. "You can tell there's some things going on over there, but they've still got a lot of young talent on their team. McGee and Blatche are going to be good in this league for a while."
IN SHORT » The Jazz extend the Wizards' misery this season, blowing them away in the second and third quarters.
KEY MOMENT » Carlos Boozer scores nine points in the final 5:36 of the second quarter to help give the Jazz a 14-point halftime lead.


text:
Model Mayhem Admin
Natasha TiffanyModel Female Los Angeles, California, US
My MM URL: http://www.modelmayhem.com/natashatiffany
Mayhem # 88575
About Me
Family is orginally born from Belize. natasha tiffany was born and raised in los angeles california . modeling has always been a passion it gives her alto ego a chance to come out and release the inner beauty as well as her outter. the camera is loved by her, but her nationality gives her a chance represent her culture that one in a million never even thought to try to become what she is going to be " BEAUTY from the eye of all beholders".
Have you worked with Natasha Tiffany? Add Credits for Natasha Tiffany! >>
Credit Notes
San Jeev-Mayhem #333400
Kami couture-Mayhem #137570
Gumption Photography-Mayhem #402277
Door 38 Images- Mayhem#481813
Shawn Kloster- Mayhem#427026
Amey Photography-Mayhem#1411985
Model Mayhem Admin
LS Studios Photography Photographer
Atomik-Gei... Design Wardrobe Stylist
Isaac Mathew White CA Model
Liberia Model
de maitres Photographer
Loading Content


text:
WA - Minimum Wage Increase
Washington's minimum wage for next yearwill likely climb to over $9 an hour when the figure is...
< Syrian Rebel Infighting
Aug 02, 2013 06:45
Category: General News
Category: General News
Temporary Asylum For Snowden In Russia
MOSCOW (AP) — Edward Snowden's Russian lawyer says the National Security Agency leaker has found a place to stay in Russia. Now, he says, Snowden has to figure out what to do with himself. Russia granted Snowden temporary asylum yesterday, allowing him to leave the Moscow airport where he had been holed up for almost six weeks. He's allowed to remain in Russia for at least a year.


text:
Landsat 7 Orthorectified Imagery over CanadaThe purpose is to promote the use of geomatics and educate by providing a Web and file transfer protocol (ftp) site that distributes Canada's geospatial data. The objective of...
Landsat 7 Level 1-G Imagery over CanadaTo educate and promote geomatics use by providing, free of charge, satellite imagery of Canada. Landsat 7 L1-G data is valuable for both commercial and educational purposes.
Landsat 5 TM Data over Major Canadian CitiesCCRS has packaged and prepared this dataset for distribution through GeoGratis to offer interested individuals the opportunity to develop expertise in the use of satellite imagery.
Geogratis - Radarsat Mosaic of Canada CollectionInitiated to provide an unique synoptic view of Canada using data acquired from Canada's first Earth Observation Satellite, this digital national mosaic has been produced at a...
CV - 580 Airborne-SAR, CanadaThe C-SAR data provides an opportunity for educational studies relating to SAR.
CanImage - Landsat 7 Orthoimages of Canada, 1:50 000CanImage GeoTIFF files can be opened in different applications in response to specific needs: geographic information systems (GISs) for land-management applications; mapping...
Вы можете получить доступ к этому реестру через API (see Документация API).


text:
Where Do You Do Your Christmas Shopping? [Poll]
The Sunday paper seems to get heavier with more ads each week.
There is no shortage of options when it comes to Christmas shopping.
Where do you do your Christmas shopping?
With so many different people and tastes to buy for, Christmas shopping can become very time consuming. We've made a list of some popular places to get that shopping done.
Of course, there are dozens of others. Check off everywhere you are Christmas shopping this year and tell us about the places you'll be visiting that didn't make the list.
I think I'll be going to all but 3 or 4 off of the list below once my shopping is done.


text:
Special Events
PEM/PM Evening Party
Members and Salem residents (with ID) free, nonmembers $10 at the door
Thursday, February 20, 2014 from 6pm - 9pm
Cash bar
Location: Peabody Essex Museum
Enjoy a riveting performance by master guitarists Randy Roos and Bruce Bartlett and hear performers (including a tap dancer) inject unexpected musical sounds into our galleries using a bamboo flute, bones, percussion and paper/scissors/stones. See a guitar-building demonstration, use tools to shape your own guitar body and visit the flock of zebra finches making music in from here to ear, our latest FreePort contemporary art installation.
Please note: Tickets for from here to ear will be available at 5 pm at the museum on a first-come, first-served basis.


text:
Rose Weasley is meant to despise Scorpius Malfoy. In...
Return to Hogwarts
- by kelskels_musical
- Rating:
- Published: 22 Mar 2014
- Updated: 23 Mar 2014
- Status: In Progress
Imagine that you are me. Yes, me. I am Rose, Rose Weasley and this year my life got totally amassing! Follow me to Hogwarts, were my uncle and my mom work hard every day. My Uncle? He is Harry Potter. My mom? Hermione Granger!
Join MovellasFind out what all the buzz is about. Join now to start sharing your creativity and passion
Loading ...


text:
About Audra
My name is Audra, and I am a senior English and Music student at Troy. I write and perform music during my downtime, and I am an aspiring performer. My primary passions are opera and Shakespearean theater. I am classified as a coloratura soprano, but, after some discoveries lately, I frankly don't know what I am.
I can be blunt, so I apologize in advance if I offend you or upset you. I am not a mean person, I swear! With that, welcome to YWS and my page! Feel free to message me, write with me, and just be a good friend to me, anytime.
Mrs. W.
animals, anime/manga, music/art, fantasy, writing, singing, Jesus, Jeff
English student, musician, actress, sales associate


text:
Pennsylvania child abuse registry posts names before due process
In Pennsylvania, a parent can be branded an abuser for spanking a child, and then remain on a state list with pedophiles and felons without the benefit of a court hearing, attorneys say.
"The process puts the cart before the horse," said Aaron Martin, a constitutional attorney with a private practice in Kennett Square, Chester County. "You are first declared guilty by the state, and then it is up to you to challenge that indication to assert your innocence."
Under state law, child protective service agencies such as county Children and Youth Services must investigate all reports of child abuse within 24 hours. When a social worker or police officer deems a report to be valid, law requires the immediate — and permanent — placement of the suspect's name on the state child abuse registry, regardless of whether police ever charge the person with a crime.
Pennsylvania's registry contained 112,580 names last year, the most recent figure available. Registry information is confidential and unavailable to the general public, but school districts, day care centers and other child service groups can use it to screen potential employees. The only way a name can be expunged from the registry is through an appeal hearing, attorneys said.
"The intent is to protect children from future abuse or neglect," said Cathy Utz, interim deputy secretary of the state Department of Public Welfare's Office of Children, Youth and Families, which maintains the registry.
Attorneys advocating on behalf of people who contend they were improperly placed on the registry said their main concern centers on what the state terms "indicated" determinations of child abuse. That's when a social worker — not a law enforcement official or judge — decides an abuse report is valid. Social workers base those decisions on an investigation, which can include medical evidence or a suspect's admission, according to the welfare department.
Nearly 88 percent of the names listed on the registry are there based on the decisions of social workers. State welfare officials said people suspected of abuse are afforded due process through appeals, and the department made system improvements over the years. Letters that are automatically sent to abuse suspects notifying them that their names are being entered into the registry and informing them of their rights were redesigned to more clearly outline those facts. The department includes abuse reports in the letters.
An officer from the welfare department's Bureau of Hearings and Appeals conducts the appeals hearings and decides the cases. Last year, nearly 23 percent of the 1,239 appeals hearings led to removal of names, according to department statistics. One percent of the decisions were upheld. Two percent of the appeals were withdrawn by appellants, and three percent of appellants were denied hearings. Seventy-one percent of the cases are pending.
Michael Race, a spokesman for the state Department of Public Welfare, said hearings take three to seven months, on average, and sometimes longer because of attorneys' postponements and procedural delays.
Attorney advocates complain the system denies people the constitutional right of due process by first placing them on the list, and the appeal process to seek removal takes too long — up to two years in some cases.
Even child advocates see potential problems.
"The registry has to be understood, and people have to have a very timely way to have their names removed so that we can assure fairness and justice," said Cathleen Palm, co-founder and executive director of the Protect Our Children Committee, a statewide coalition of child advocates. "If people don't trust the system, then, ultimately, we can't have the safest system for kids."
Some lawmakers have taken notice.
Sen. Kim Ward, R-Greensburg, who chairs the Aging and Youth Committee, said the committee plans to hold hearings this summer on problems with ChildLine, a 24-hour, state-operated hotline for reporting child abuse tips. She said the hearings should include discussion of any problems with the registry.
"First and foremost, we want to make sure the kids are protected," Ward said. "But we don't want to have people out there who haven't had their just due process. This is something that I will be following up on."
Sen. Ted Erickson, R-Newtown Square, Delaware County, introduced legislation two years ago that would have required holding hearings within 30 days of an appeal and ruling on a case within 45 days. His bill died because it lacked Senate support.
"We're going to try and take a look to see if we can get more support, and I will introduce it if we can," Erickson said.
Critics say legislators and policy makers are reluctant to change the system because they do not want to appear soft on child abusers.
"Over the years, we have tried to address this subject with legislators, and it's a politically touchy subject with them," said Janet Ginzberg, an attorney with Community Legal Services of Philadelphia who has defended numerous people accused of child abuse.
By law, people found guilty in court of child abuse cannot work with children for at least five years after a conviction.
Utz said schools or child care agencies must get permission from a job applicant to check whether that person is on the registry. She noted that "indicated" reports alone cannot legally prevent a person from getting a job.
But Sara Rose, a staff attorney with the American Civil Liberties Union in Pittsburgh, said chances of employment are slim when a person's name appears on the registry.
"There's no law prohibiting a child agency from hiring someone on this list, but I think it's a very low chance that you're going to be hired," Rose said.
Attorneys typically use pseudonyms or initials in lawsuits to identify clients suing to have their names removed from the registry. They said they do it to maintain confidentiality.
"I think people are understandably reluctant to be identified," Rose said.
Pennsylvania's child abuse registry isn't the only one drawing criticism.
A North Carolina appeals court last year declared that state's registry unconstitutional because it did not permit accused abusers hearings before they were listed, The Associated Press reported. Attorneys in New York filed a class-action suit in that state on behalf of thousands of people for the same reason.
Reports of flaws on the state level are delaying the creation of a nationwide child abuser database that Congress authorized in 2006.
"There's been litigation in a number of states over the years around due process and central registries," said Howard Davidson, director of the American Bar Association's Center on Children and the Law. "The best due process would be to withhold (entering a person's name) until an appeal has been resolved."


text:
Toxicologist wary of adding medicinal properties to wine
Leading NZ toxicologist wary of adding some medicinal properties to wine
September 16, 2013
A leading New Zealand toxicologist is in two minds about applying medicinal additives to food or wine.
University of Canterbury (food) expert Professor Ian Shaw says the concept of adding chemicals with medicinal properties to food has been around for hundreds of year. But he says people are really just become much more acutely aware of the benefits and pitfalls.
Professor Shaw, Co-Director of UC's Food Safety Centre, will give a public lecture this week (Wednesday, September 18) about what if food and wine were medicines. See details here: https://www.eventbrite.co.nz/event/7990410533
``People are now selecting food according to the chemicals they contain. Companies are promoting the fact their food contains vitamins and other healthy elements. We're now getting more specific about what we want to eat.
``Is it right to add medicines to food, water and wine to mass medicate consumers? The answers are yes and no. Of course it is right to add some things.
``In New Zealand we have very low levels of iodine in the soil and environment generally because we are a volcanic nation. With not enough iodine in our food we get more goitre which means more thyroid cancer.
``So it makes a lot of sense to put iodine in food to stop that happening. Nobody would argue with that. We fortify our bread with salt which contains iodine to ensure everyone gets enough iodine.
``But at the other end of the spectrum is a chemical called resveratrol which is present in grapes and blueberries so is therefore present in tiny levels in wine.
``This chemical has been shown to have all sorts of beneficial properties such as extending life or preventing heart attacks and neurological diseases. Some companies are considering adding this to wine and creating a new market for people who would not normally drink wine but who might start drinking it feeling they may live longer. Now I am not sure that is a good idea.
``A lot of research papers say how good it is. But we are slowly starting to see other views. Some say resveratrol's properties look a bit like the female hormone which means it could promote breast cancer. Would it? I don't know. So to me to add that to our food would be too risky. Because we don't yet know what the risks are.
``Seaweed contains high levels of iodine, which prevents goitre, but should iodine deficient New Zealanders be force fed seaweed or should iodine be added to our daily bread? Spina bifida is a terrible birth defect caused by a lack of folate in food, but should we force everyone to consume more folate?
``What are the negative effects of eating too much folate? Are these risks outweighed by the benefit of preventing a few spina bifida cases in New Zealand each year? Fluoride is highly toxic, but at very low doses it prevents dental caries; so, why is there so much fuss about adding fluoride to drinking water?''


text:
Anzac Cove: minister ducks for cover again
Page Tools
ANZAC Cove is a pivotal place in the Australian imagination. John Howard understands this all too well. That is why he made the curious suggestion in April that the site the sovereign territory of another nation should be placed on Australia's national heritage list.
It was a notion given short shrift by the Turkish Government, which scarcely needed to remind the supplicant prime minister that the Gallipoli Peninsula is, after all, not part of the Australian landscape. Mr Howard's diversionary move needs, however, to be seen in the context of the colossal blundering that occurred at the site shortly before, largely at the behest of the Australian Government.
Not only is Anzac Cove deeply significant to Australians, but there is a real danger of them loving it to death. Long ignored, the site of the defining campaign of an infant nation in World War I has become a place of constant pilgrimage. Over the past decade, an increasing number of Australians of all ages have come to the place. While still relatively remote, it has become just another stop on the backpacker trail. On Anzac Day itself, the date commemorating the initial landing of what would become a spectacular military failure, around 20,000 mainly young Australians and New Zealanders now gather almost twice as many as the number who took the beach and some of the nearby hills in 1915.
The solemnity of the official commemorations has been overtaken in part by the festivities attached to the arrival of a human tide dominated by backpackers in their 20s. Last April, the incongruity of the Bee Gees hits Stayin' Alive and You Should Be Dancin' being played to the waiting crowd was not lost on those angered by what had occurred in the weeks before.
Last Thursday, a Senate committee handed down a damning report into the Government's failure to investigate bungled roadworks at the site of the Gallipoli landings. Those works, which historians say have radically altered the original landscape and destroyed some features altogether, apparently unearthed some human remains that had lain undisturbed on the battlefield. The debacle came to light after it was reported extensively in The Sunday Age and The Age earlier this year. Despite desperate attempts by the Government to play down the impact of the project, which it had encouraged the Turkish authorities to undertake, the physical damage wrought by the bulldozers is done.
Journalist and Gallipoli historian Les Carlyon bemoans the fact that the original route of the diggers inland from the cove has been fairly well obliterated. Instead, there is now a wider road and extensive car parking, including a VIP section, aimed at catering for the one day of the year when the big crowds come.
Last week's Senate finding merely confirms what many independent witnesses have already recorded. It goes almost without saying that the Federal Government has rejected the committee's conclusions, including that the Government failed to safeguard the site properly or work with the Turkish authorities to preserve its integrity.
While Veterans Affairs Minister De-Anne Kelly was dismissive of the findings, the debacle and its aftermath haven't stopped her from moving to unceremoniously bundle out retired air vice-marshal Gary Beck as head of the war graves office. Mr Beck, who visited the site repeatedly before and during the roadworks, should have reported what was happening. He failed to do so, arguing it was not part of his brief. By failing to act, Mr Beck has offered himself up as a convenient scapegoat for the person who should be held to account: Minister Kelly. It seems that her failure will go unpunished. But that is scarcely a surprise in a Government where the doctrine of ministerial responsibility was bulldozed long ago by a PM who holds that Westminster convention in contempt.


text:
Padron Serie 1926 No. 2 Belicoso
Padron Serie 1926 No. 2
Padron Serie 1926 No. 2 Belicoso 5 Pack
Padron Serie 1926 No. 2 4 Pack
A gorgeous, box-pressed Figurado with a dark, oily Nicaraguan Maduro wrapper that caps a full-bodied blend of vintage, 5-year-aged Nicaraguan Ligero tobaccos. Padron Serie 1926 Belicoso cigars are sought for their bold, spicy flavor and thick, heady smoke. (Intended for more experienced smokers.)
If there is an award for Finest Smoke On The Planet, this is definitely the winner...
My wife got me a box of 10 for Christmas. well, they are gone now! every one of them was a perfect smoke in every way!
On this day of the Kentucky Derby, $20 on a 50-1 horse! Yes Yes Yes. Wow, A day for this and my first time smoking it. Gorgeous, first thing i am doing with the winnings is buying a box for my humidor. Thank you lord Jesus!
I just recently got back into cigars. I have always smoked mild, but decided to give the full a try. These cigars are truly amazing. Well worth the price. I only smoke 2 to 3 cigars a week, so its a treat.


text:
FL Library Removes "50 Shades Of Grey" From Shelves
50 Shades Of Grey may well be one of the worst-written books ever. But being a blight on the face of literature isn't the reason Brevard County Public Library in Florida pulled the BDSM erotica novel from shelves: they called 50 Shades "pornography." But Brevard County is not consistent in what they consider "pornographic" and what they consider simply "erotic"; The New York Times found other sexy books on the shelves, like The Complete Kama Sutra and Lolita. A spokesman for the county government said the latter books were acceptable because they had "become part of the societal mainstream." Here's hoping this is the work of overzealous local government officials, not librarians themselves. In any case, is this a plus-one in the Florida column for keeping such terrible writing away from readers? Or a minus-one for censorship? I'm not even sure. [NY Times]


text:
Welcome to The Mystic Sea! Welcome to the realm of Mara Gimel. Mara Gimel means Camel Of The Mystic Sea. It is my role to lead you through this world of the occult, the unseen and the unexplained. Enter this realm with an open mind, it's time to remember what you have forgotten.
Thursday, 17 January 2013
A UFO on the Moon?
Daily Mail: Is 2013 the year we finally make contact with our brothers from beyond the stars? One Youtube user certainly seems to think it's a possibility. The user, danchek2013, has uploaded a video he claims shows footage of at at least one mysterious object zipping about over the surface of the moon. One of the 'craft' emerges from the shadowy landscape of the moon's surface and then seemingly accelerates over the craters, before changing direction at breakneck speed and heading towards the bottom of the screen...read more>>>..


text:
As you may recall from last week, researchers surveyed about 2,500 adult males and discovered 46 differences between those never in Scouts, those in Scouts for a while, and Eagle Scouts. Since we worked on advancement tonight, I'll concentrate on those differences related to setting and reaching goals.
Just by being in Scouts, you will be 40% more likely to continue taking at least one educational course every year. If you make Eagle, then you will be 80% more likely to continue taking education throughout your life. As you find with requirements and merit badges, learning is important to reach your goals.
And, when it comes to results, if you make Eagle, you will be 30% more likely to reach your job-related goals, 50% more likely to reach personal goals, 50% more likely to reach financial goals, every year, and 80% more likely to reach your spiritual goals.
I hope this little bit of information encourages you to set and reach your goals. Just by being in Scouts, you get a taste of what it means to have and reach some goals, and, not surprising, going for Eagle really teaches you what it means to set and achieve goals, not just in Scouts, but for the rest of your life.
Source: http://blog.scoutingmagazine.org/2012/04/10/new-study-shows-46-ways-eagle-scouts-are-different/


text:
Mike Schiffman's Articles
On Information Entropy
In this blog post you will learn about entropy within the domain of information theory. You will learn what entropy is and how to compute it. You will be shownRead More
A Brief History of Malware Obfuscation: Part 2 of 2
We parted ways last time with a discussion of polymorphism that left you tantalized and on the heels of a malware revolution…MetamorphismFrom the Greek meta meaning about or self.From the GreekRead More
A Brief History of Malware Obfuscation: Part 1 of 2
To Hide is to ThriveMalware is just plain insidious. It can do very wicked things on a very large scale. Ostensibly, to do the dirt, malware must fly under theRead More
The Common Vulnerability Reporting Format
To date, a major gap exists in vulnerability standardization: there is no standard framework for the creation of vulnerability report documentation. While the computer security collective has done a bang-upRead More


text:
Have Parenting Questions? Ask a Parenting Counselor for Answers
Good evening/early morning. I would like to help you today.
I think that you did a wonderful job addressing the situation. The wording that you used to explain to the children how it is inappropriate to kiss, (both for their age and the fact that they are relatives) was perfect, I couldn't have said it better myself. In terms of discussing it further, no I do not think that it will be necessary, unless another similar situation occurs. I do think that you should speak to your nieces' father (your brother) about what took place, and how you handled it, so that he can keep an eye out for his daughter, and correct any related behavior she may be showing elsewhere. I also think that the next time the children come together, you let them know that no more pillow fighting or wrestling will be allowed. Give them some other options of things to do; board games, sports, bike riding, roller skating; something that involves less physical contact. I think that your son and your niece are old enough to understand why the change has occurred.
I think that the first step is to help the situation so that it can't occur. Don't allow the two to be away from supervision (doors closed or such). Also set the proper sleeping arrangements, I suggest them in separate rooms. If it does occur again, you should contact your brother, and let him know what occurred. I would recommend having him pick her up, and letting the two of them know that your niece will not be able to sleep over again for some time, until you feel that you can trust her not to try kissing your son.
Also, know that this is not uncommon. Children are experimental at this age; and cousins are generally not as close as brother and sister, kind of like friends in their own minds, so they would feel comfortable experimenting with a cousin.


text:
Skip to Content
Home > Wellness Resources > Health Library > Shoulder SLAP Tear
A SLAP tear is an injury to a piece of shoulder cartilage called the
labrum. This cartilage surrounds the shoulder socket, helping to keep it stable
when you move. Your arm muscle (biceps) is attached to your shoulder by a
biceps tendon. This tendon connects your biceps to the labrum at the top of the
shoulder joint. A SLAP tear happens when the labrum is damaged where the biceps
tendon is attached.
This picture shows one type of SLAP tear. SLAP stands for Superior
Labrum Anterior to Posterior.
ByHealthwise StaffPrimary Medical ReviewerWilliam H. Blahd, Jr., MD, FACEP - Emergency MedicineSpecialist Medical ReviewerPatrick J. McMahon, MD - Orthopedic Surgery
Current as ofMay 23, 2016
Current as of:
May 23, 2016
Healthwise Staff
Medical Review:
William H. Blahd, Jr., MD, FACEP - Emergency Medicine & Patrick J. McMahon, MD - Orthopedic Surgery
This information does not replace the advice of a doctor. Healthwise, Incorporated, disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use. Learn how we develop our content.
To learn more about Healthwise, visit Healthwise.org.
© 1995-2016 Healthwise, Incorporated. Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.


text:
Apple Popcorn Brittle
Makes about 7 cups. Recipe is from The Popcorn Board.
1 quart popped popcorn
2 cups apple-cinnamon cereal
1 cup peanuts
3/4 cup apple juice
1 cup sugar
1/4 cuplight corn syrup
1/2 tsp. vinegar
1/4 tsp. salt
1. In a bowl, toss together popcorn, cereal and peanuts. Set aside.
2. Butter the sides of a heavy, 2-quart saucepan. Combine the apple juice, sugar, corn syrup, vinegar and salt, and cook over medium heat, stirring constantly, until the sugar dissolves and the mixture begins to boil.
3. Cook to hard-ball stage, 250 degrees on a candy thermometer, and remove from heat. Pour the syrup over the popcorn mixture and toss to coat.
4. Spread in a buttered 151/2-by-101/2-by-1-inch baking pan. Cool until hardened. Break into pieces.


text:
My name is Debbie and I live in Central Massachusetts. I am a mom of 2, a grandma to Jace and a "Mama Stone" (as I'm called) to about 25 rental kids as I call them. I consider myself to be a serious maybe even (as all my kids would say, "Obsessed" photographer. If it moves I photograph it, if breaths I photograph it, if it doesn't breath I photograph it and if it doesn't move I photograph it even more. Ok, so my kids are right, I'm obsessed. I never leave home with out it, my camera that is. I've always loved photography but as I've headed into my mid-life crisis period I have begun to open my eyes to more of the wonder around me. Why it took so long I don't know but look out world I have arrived. Now I have a thirst to make up for lost time and I love Wunderground and all of the wunderful photographers I get to share my world with. I absolutely love seeing everyones photos from around the world and for that I thank all of you for your wonderful generosity for sharing them with me and us on this great site. Smile say cheese now!!
Snow Romp
Uploaded by: stoneygirl
Sunday March 10, 2013
Auburn, MA (Current Weather Conditions)
Caption: Keira is definitely enjoying this snow much more than I am. She was romping all around the front yard with her nose in the snow. She only looked at me when I called her name and then went right back to putting her nose in the snow. It's a husky kind of weather for sure.
EXIF Data
Manufacturer: Canon
Model: Canon EOS REBEL T2i
Orientation: top - left
x-Resolution: 350.00
y-Resolution: 350.00
Resolution Unit: Inch
Software: Digital Photo Professional
YCbCr Positioning: centered
Copyright: [None] (Photographer) - (Editor)
Exposure Time: 1/500 sec.
FNumber: f/7.1
ISO Speed Ratings: 3200
Exif Version: Exif Version 2.21
Components Configuration: Y Cb Cr -
Shutter speed: 9.00 EV (APEX: 22, 1/512 sec.)
Aperture: 5.62 EV (f/7.0)
Exposure Bias: 0.00 EV
Flash: Flash did not fire, compulsory flash mode.
Focal Length: 300.0 mm
User Comment:
FlashPixVersion: FlashPix Version 1.0
Color Space: sRGB
PixelXDimension: 5184
PixelYDimension: 3456
Focal Plane x-Resolution: 5728.18
Focal Plane y-Resolution: 5808.40
Focal Plane Resolution Unit: Inch
Custom Rendered: Normal process
Exposure Mode: Auto exposure
White Balance: Auto white balance
Scene Capture Type: Standard


text:
Do I need a new head gasket?
5 Attachment(s)
Do I need a new head gasket based on the pics?
I can't tell if this is coolant foaming or just oil wax build up??
When I un-screw the oil filler cap there are some water droplets but I was wondering if that may just be from condensation in the engine as the cap seams to seal pretty well.
Model: 1998 M3
Engine: S52, 3.2L, 6 Cyl.
Oil: Mobil 1 synthetic, 10W30 or 10W40 based on season
Mileage: 102,000
You can't tell from just that.
That could be condensation from blowby. Happens in cold weather, especially with short runs that do not get the entire engine fully up to temp.
See this a lot in aircraft engines.
|All times are GMT -7. The time now is 08:08 AM.
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2017, vBulletin Solutions, Inc.
© 2001- VerticalScope Inc. All rights reserved.